Insmed Incorporated (NASDAQ:INSM) Shares Sold by Beacon Financial Advisory LLC

Beacon Financial Advisory LLC decreased its position in shares of Insmed Incorporated (NASDAQ:INSM) by 15.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,675 shares of the biopharmaceutical company’s stock after selling 2,150 shares during the quarter. Beacon Financial Advisory LLC’s holdings in Insmed were worth $852,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of INSM. V Square Quantitative Management LLC purchased a new position in shares of Insmed during the 3rd quarter valued at about $30,000. GAMMA Investing LLC lifted its holdings in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 224 shares during the period. First Horizon Advisors Inc. boosted its position in Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 287 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the period. Finally, EntryPoint Capital LLC purchased a new position in shares of Insmed during the 1st quarter valued at approximately $33,000.

Insmed Stock Performance

NASDAQ:INSM opened at $69.30 on Wednesday. The company’s 50-day moving average is $72.73 and its two-hundred day moving average is $62.38. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a market capitalization of $11.91 billion, a price-to-earnings ratio of -12.49 and a beta of 1.12. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. During the same quarter in the prior year, the firm earned ($1.10) earnings per share. Insmed’s revenue was up 18.1% compared to the same quarter last year. Analysts forecast that Insmed Incorporated will post -5.36 EPS for the current year.

Insider Activity at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the transaction, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Martina M.D. Flammer sold 13,436 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at $7,951,559.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael Alexander Smith sold 27,871 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the transaction, the insider now directly owns 67,856 shares of the company’s stock, valued at $5,045,093.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,882 shares of company stock worth $5,765,446. Insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

INSM has been the topic of several analyst reports. The Goldman Sachs Group raised their price target on shares of Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. Guggenheim lifted their target price on shares of Insmed from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Bank of America upped their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. lifted their price objective on Insmed from $72.00 to $74.00 and gave the stock an “overweight” rating in a report on Thursday, October 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $83.07.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.